Eicosanoids and docosanoids in plasma and aorta of healthy and atherosclerotic rabbits

Journal of Vascular Research

Volumn 50, Issue 5, 2013, Pages 372-382

  Szklenar, Monika ^a,b   Kalkowski, Janine ^d   Stangl, Verena ^d   Lorenz, Mario ^d   Rühl, Ralph ^a,b,c  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b Paprika Bioanalytics BT   (Germany)

^c INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Atherosclerosis; Docosanoids; Eicosanoids; Polyunsaturated fatty acids; Rabbit

Indexed keywords

12 HYDROXYICOSATETRAENOIC ACID; 13 OXO OCTADECADIENOIC ACID; ARACHIDONATE 12 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONIC ACID; DOCOSANOID; ICOSANOID; LIGAND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; POLYUNSATURATED FATTY ACID; UNCLASSIFIED DRUG; LEUKOTRIENE B4; LIPID; LIPOXYGENASE; PROSTAGLANDIN SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INFLAMMATION; LIPID DIET; METABOLITE; NONHUMAN; PLASMA; PRIORITY JOURNAL; RABBIT; ANIMAL TISSUE; ATHEROSCLEROTIC PLAQUE; BLOOD LEVEL; CHOLESTEROL DIET; MALE; NEW ZEALAND WHITE (RABBIT);

EID: 84881531340     PISSN: 10181172     EISSN: 14230135     Source Type: Journal    
DOI: 10.1159/000350865     Document Type: Article

References (36)

1. Blaho VA, Buczynski MW, Brown CR, Dennis EA: Lipidomic analysis of dynamic eicosanoid responses during the induction and resolution of Lyme arthritis. J Biol Chem 2009; 284: 599-612.
2. Buczynski MW, Dumlao DS, Dennis EA: Thematic review series: proteomics. An integrated omics analysis of eicosanoid biology. J Lipid Res 2009; 50: 1015-1038.
3. Shiraki T, Kamiya N, Shiki S, Kodama TS, Kakizuka A, Jingami H: Alpha, beta-unsaturated ketone is a core moiety of natural ligands for covalent binding to peroxisome proliferator-activated receptor gamma. J Biol Chem 2005; 280: 14145-14153. (Pubitemid 40517317)
4. Quehenberger O, Armando AM, Brown AH, et al: Lipidomics reveals a remarkable diversity of lipids in human plasma. J Lipid Res 2010; 51: 3299-3305.
5. Bannenberg G, Arita M, Serhan CN: Endogenous receptor agonists: resolving inflammation. ScientificWorldJournal 2007; 7: 1440-1462. (Pubitemid 47439737)
6. Dennis EA, Deems RA, Harkewicz R, et al: A mouse macrophage lipidome. J Biol Chem 2010; 285: 39976-39985.
7. Gomolka B, Siegert E, Blossey K, Schunck WH, Rothe M, Weylandt KH: Analysis of omega-3 and omega-6 fatty acid-derived lipid metabolite formation in human and mouse blood samples. Prostaglandins Other Lipid Mediat 2011; 94: 81-87.
8. Yue H, Jansen SA, Strauss KI, et al: A liquid chromatography/mass spectrometric method for simultaneous analysis of arachidonic acid and its endogenous eicosanoid metabolites prostaglandins, dihydroxyeicosatrienoic acids, hydroxyeicosatetraenoic acids, and epoxyeicosatrienoic acids in rat brain tissue. J Pharm Biomed Anal 2007; 43: 1122-1134. (Pubitemid 46185820)
9. Masoodi M, Mir AA, Petasis NA, Serhan CN, Nicolaou A: Simultaneous lipidomic analysis of three families of bioactive lipid mediators leukotrienes, resolvins, protectins and related hydroxy-fatty acids by liquid chromatography/electrospray ionisation tandem mass spectrometry. Rapid Commun Mass Spectrom 2008; 22: 75-83. (Pubitemid 351156118)
10. Kita Y, Takahashi T, Uozumi N, Shimizu T: A multiplex quantitation method for eicosanoids and platelet-activating factor using columnswitching reversed-phase liquid chromatography-tandem mass spectrometry. Anal Biochem 2005; 342: 134-143. (Pubitemid 40805637)
11. Galkina E, Ley K: Immune and inflammatory mechanisms of atherosclerosis. Annu Rev Immunol 2009; 27: 165-197.
12. Glass CK, Witztum JL: Atherosclerosis: the road ahead. Cell 2001; 104: 503-516. (Pubitemid 32201946)
13. Yanni AE: The laboratory rabbit: an animal model of atherosclerosis research. Lab Anim 2004; 38: 246-256. (Pubitemid 38962073)
14. Linton MF, Fazio S: Cyclooxygenase products and atherosclerosis. Drug Discov Today Ther Strateg 2008; 5: 25-36.
15. Cipollone F, Cicolini G, Bucci M: Cyclooxygenase and prostaglandin synthases in atherosclerosis: recent insights and future perspectives. Pharmacol Ther 2008; 118: 161-180.
16. Zhao L, Moos MP, Grabner R, et al: The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nat Med 2004; 10: 966-973. (Pubitemid 39273738)
17. Burleigh ME, Babaev VR, Yancey PG, et al: Cyclooxygenase-2 promotes early atherosclerotic lesion formation in ApoE-deficient and C57BL/6 mice. J Mol Cell Cardiol 2005; 39: 443-452. (Pubitemid 41133730)
18. Wittwer J, Hersberger M: The two faces of the 15-lipoxygenase in atherosclerosis. Prostaglandins Leukot Essent Fatty Acids 2007; 77: 67-77. (Pubitemid 47539103)
19. Sears DD, Miles PD, Chapman J, et al: 12/15-lipoxygenase is required for the early onset of high fat diet-induced adipose tissue inflammation and insulin resistance in mice. PLoS One 2009; 4:e7250.
20. Reilly KB, Srinivasan S, Hatley ME, et al: 12/15-Lipoxygenase activity mediates inflammatory monocyte/endothelial interactions and atherosclerosis in vivo. J Biol Chem 2004; 279: 9440-9450. (Pubitemid 38296011)
21. Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM: Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR?. Cell 1998; 93: 229-240. (Pubitemid 28180856)
22. Laffitte BA, Tontonoz P: Orphan nuclear receptors find a home in the arterial wall. Curr Atheroscler Rep 2002; 4: 213-221.
23. Ruhl R: Method to determine 4-oxo-retinoic acids, retinoic acids and retinol in serum and cell extracts by liquid chromatography/diodearray detection atmospheric pressure chemical ionisation tandem mass spectrometry. Rapid Commun Mass Spectrom 2006; 20: 2497-2504. (Pubitemid 44258456)
24. Kita Y, Takahashi T, Uozumi N, Nallan L, Gelb MH, Shimizu T: Pathway-oriented profiling of lipid mediators in macrophages. Biochem Biophys Res Commun 2005; 330: 898-906. (Pubitemid 40462171)
25. Csanky E, Ruhl R, Scholtz B, Vasko A, Takacs L, Hempel WM: Lipid metabolite levels of prostaglandin D2 and eicosapentaenoic acid recovered from bronchoalveolar lavage fluid correlate with lung function of chronic obstructive pulmonary disease patients and controls. Electrophoresis 2009; 30: 1228-1234.
26. Lorenz M, Fechner M, Kalkowski J, et al: Effects of lycopene on the initial state of atherosclerosis in New Zealand White (NZW) rabbits. PLoS One 2012; 7:e30808.
27. Masoodi M, Nicolaou A: Lipidomic analysis of twenty-seven prostanoids and isoprostanes by liquid chromatography/electrospray tandem mass spectrometry. Rapid Commun Mass Spectrom 2006; 20: 3023-3029. (Pubitemid 44569781)
28. Yang J, Eiserich JP, Cross CE, Morrissey BM, Hammock BD: Metabolomic profiling of regulatory lipid mediators in sputum from adult cystic fibrosis patients. Free Radic Biol Med 2012; 53: 160-171.
29. Gertow K, Nobili E, Folkersen L, et al: 12-and 15-lipoxygenases in human carotid atherosclerotic lesions: associations with cerebrovascular symptoms. Atherosclerosis 2011; 215: 411-416.
30. Jacob S, Laury-Kleintop L, Lanza-Jacoby S: The select cyclooxygenase-2 inhibitor celecoxib reduced the extent of atherosclerosis in apo E-/-mice. J Surg Res 2008; 146: 135-142. (Pubitemid 351442932)
31. Zagryagskaya AN, Aleksandrov DA, Pushkareva MA, Galkina SI, Grishina ZV, Sud'ina GF: Biosynthesis of leukotriene B4 in human polymorphonuclear leukocytes: regulation by cholesterol and other lipids. J Immunotoxicol 2008; 5: 347-352.
32. Spanbroek R, Grabner R, Lotzer K, et al: Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc Natl Acad Sci USA 2003; 100: 1238-1243. (Pubitemid 36183986)
33. Qiu H, Gabrielsen A, Agardh HE, et al: Expression of 5-lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability. Proc Natl Acad Sci USA 2006; 103: 8161-8166. (Pubitemid 43801069)
34. Cao RY, St Amand T, Grabner R, Habenicht AJ, Funk CD: Genetic and pharmacological inhibition of the 5-lipoxygenase/leukotriene pathway in atherosclerotic lesion development in ApoE deficient mice. Atherosclerosis 2009; 203: 395-400.
35. Ceriello A: Thiazolidinediones as anti-inflammatory and anti-atherogenic agents. Diabetes Metab Res Rev 2008; 24: 14-26. (Pubitemid 351175996)
36. Tikellis C, Jandeleit-Dahm KA, Sheehy K, et al: Reduced plaque formation induced by rosiglitazone in an STZ-diabetes mouse model of atherosclerosis is associated with downregulation of adhesion molecules. Atherosclerosis 2008; 199: 55-64.